BNIP3P22

Across TCGA pan-cancer cohorts, BNIP3P22 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated BNIP3P22 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher BNIP3P22 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated BNIP3P22 expression acts as an unfavorable survival marker, although some lineages such as BLCA and LUAD show a favorable association.

LIHC, COAD, and BLCA are the cancer types where BNIP3P22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.356	0.546	<.001	78	view →
COAD	DFS	Tertile	III,IV	0.182	0.691	<.001	63	view →
BLCA	OS	Quartile	II,III,IV	0.854	0.675	<.001	49	view →
ACC	DFS	Quartile	IV	0.058	0.447	.002	47	view →
DLBC	DFS	Tertile	IV	0.128	1.000	.017	32	view →
LUAD	OS	Median	III,IV	0.427	0.230	.015	24	view →
KICH	DFS	Quartile	II,III,IV	0.248	0.937	<.001	22	view →
SKCM	DFS	Tertile	IV	0.749	0.188	.025	21	view →
PAAD	DFS	Tertile	III,IV	0.118	0.734	.014	18	view →
LUSC	OS	Tertile	IV	0.001	0.651	.025	18	view →
READ	DFS	Tertile	IV	0.027	0.636	<.001	18	view →
UCEC	DFS	Tertile	IV	0.237	0.570	.047	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

BNIP3P22–LIHC (OS)

Open the LIHC breakdown →